149 related articles for article (PubMed ID: 38415341)
21. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
24. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.
Kim DY; Toan BN; Tan CK; Hasan I; Setiawan L; Yu ML; Izumi N; Huyen NN; Chow PK; Mohamed R; Chan SL; Tanwandee T; Lee TY; Hai TTN; Yang T; Lee WC; Chan HLY
Clin Mol Hepatol; 2023 Apr; 29(2):277-292. PubMed ID: 36710606
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.
Chen J; Tang D; Xu C; Niu Z; Li H; Li Y; Zhang P
Lab Med; 2021 Jul; 52(4):381-389. PubMed ID: 33159511
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.
Lai K; Zhang C; Ke W; Gao Y; Zhou S; Liu L; Yang Y
Clin Drug Investig; 2017 Mar; 37(3):233-247. PubMed ID: 27928739
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
28. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B.
Wun YT; Dickinson JA
Cochrane Database Syst Rev; 2003; (2):CD002799. PubMed ID: 12804438
[TBL] [Abstract][Full Text] [Related]
29. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Jackson S; Ryder S; Cramp M; Stein K
Br J Cancer; 2008 Apr; 98(7):1166-75. PubMed ID: 18382459
[TBL] [Abstract][Full Text] [Related]
30. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis.
Su TH; Peng CY; Chang SH; Tseng TC; Liu CJ; Chen CL; Liu CH; Yang HC; Chen PJ; Kao JH
J Formos Med Assoc; 2022 Mar; 121(3):703-711. PubMed ID: 34452785
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.
Qian MY; Yuwei J R; Angus P; Schelleman T; Johnson L; Gow P
J Gastroenterol Hepatol; 2010 May; 25(5):951-6. PubMed ID: 20546449
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
[TBL] [Abstract][Full Text] [Related]
34. A Novel Diagnostic Model for Early Hepatitis B Virus-Related Hepatocellular Carcinoma Diagnosis.
Li S; Liu D; Wang Q
Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649525
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in China.
Cui T; Zhang X; Wang Q; Yue N; Bao C; Jiang R; Xu S; Yuan Z; Qian Y; Chen L; Hang H; Zhang Z; Sun H; Jin H
Hepatol Res; 2024 Feb; 54(2):142-150. PubMed ID: 37706554
[TBL] [Abstract][Full Text] [Related]
38. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
Xu F; Zhang L; He W; Song D; Ji X; Shao J
Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
[TBL] [Abstract][Full Text] [Related]
39. Cost-Utility Analysis of Non-Contrast Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance in Cirrhosis.
Decharatanachart P; Pan-Ngum W; Peeraphatdit T; Tanpowpong N; Tangkijvanich P; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
Gut Liver; 2024 Jan; 18(1):135-146. PubMed ID: 37560799
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China.
Wang Y; Shi JF; Wang L; Yan Y; Yao H; Dai M; Chen T; Qu C
Int J Infect Dis; 2019 Jan; 78():130-139. PubMed ID: 30466898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
